70 related articles for article (PubMed ID: 11056949)
1. Fungi test for evaluation of new antiandrogenic molecule.
Cabeza M; Quiroz A; Bratoeff E; Heuze I; Ramírez E; Murillo E
Proc West Pharmacol Soc; 2000; 43():29-30. PubMed ID: 11056949
[TBL] [Abstract][Full Text] [Related]
2. 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E; Flores E
Proc West Pharmacol Soc; 2002; 45():164-5. PubMed ID: 12434569
[TBL] [Abstract][Full Text] [Related]
3. New 5alpha-reductase inhibitors: in vitro and in vivo effects.
Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; Ramírez E; Naranjo-Rodríguez E
Steroids; 2005 Mar; 70(3):217-24. PubMed ID: 15763601
[TBL] [Abstract][Full Text] [Related]
4. Antiandrogenic effect of new synthetic steroids.
Cabeza M; Quiroz A; Heuze I; Bratoeff E; Herrera H; Ramírez E; Murillo E
Proc West Pharmacol Soc; 2000; 43():31-2. PubMed ID: 11056950
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the chemistry and pharmacological activity of new steroidal antiandrogens and 5 alpha-reductase inhibitors.
Bratoeff E; Cabeza M; Ramirez E; Heuze Y; Flores E
Curr Med Chem; 2005; 12(8):927-43. PubMed ID: 15853706
[TBL] [Abstract][Full Text] [Related]
7. Steroidal antiandrogens and 5alpha-reductase inhibitors.
Bratoeff E; Ramírez E; Murillo E; Flores G; Cabeza M
Curr Med Chem; 1999 Dec; 6(12):1107-23. PubMed ID: 10519917
[TBL] [Abstract][Full Text] [Related]
8. Effect of a novel steroid (PM-9) on the inhibition of 5alpha-reductase present in Penicillium crustosum broths.
Flores E; Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E
Steroids; 2003 Mar; 68(3):271-5. PubMed ID: 12628690
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor.
Ko HC; Jusko WJ
Pharmacotherapy; 1995; 15(4):509-11. PubMed ID: 7479205
[TBL] [Abstract][Full Text] [Related]
10. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic and binding activities of 5 alpha-reductase and androgen receptors in hamster prostate.
Cabeza M; Bratoeff E; Heuze I; Ramírez E; Sánchez M; Flores E
Proc West Pharmacol Soc; 2003; 46():128-31. PubMed ID: 14699908
[No Abstract] [Full Text] [Related]
12. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
15. Effect of beta-sitosterol as inhibitor of 5 alpha-reductase in hamster prostate.
Cabeza M; Bratoeff E; Heuze I; Ramírez E; Sánchez M; Flores E
Proc West Pharmacol Soc; 2003; 46():153-5. PubMed ID: 14699915
[No Abstract] [Full Text] [Related]
16. 5Alpha-reductase inhibition activity of steroids isolated from marine soft corals.
Radhika P; Cabeza M; Bratoeff E; García G
Steroids; 2004 Jul; 69(7):439-44. PubMed ID: 15246773
[TBL] [Abstract][Full Text] [Related]
17. [Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments].
Laszczyńska M; Chorzepa-Nowicka K; Wylot M; Piasecka M; Gaczarzewicz D
Pol Merkur Lekarski; 2008 Dec; 25(150):528-30. PubMed ID: 19205388
[TBL] [Abstract][Full Text] [Related]
18. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
19. [Epididymis in an experimental model of DHT deficiency: immunolocalization of ERalpha and ERbeta in rat epididymal epithelial cells. In vivo and in vitro studies].
Kolasa A
Ann Acad Med Stetin; 2006; 52(2):13-21; discussion 21. PubMed ID: 17633123
[TBL] [Abstract][Full Text] [Related]
20. Comparison of microvessel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: a preliminary study.
Kaya C; Ozyurek M; Turkeri LN
Int J Urol; 2005 Feb; 12(2):194-8. PubMed ID: 15733115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
